Organization (Industry)
ConvaTec (United Kingdom)
ClinicalTrials.gov lists ConvaTec (United Kingdom) as lead sponsor of 46 trials.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 2 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Damienwiki, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers ConvaTec (United Kingdom): 46 lead-sponsored trials and 1 legal-entity registration.
Disease areas (34)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Diabetes Mellitus | 11 |
| Diabetic Foot | 8 |
| Diabetic Neuropathies | 8 |
| Varicose Ulcer | 8 |
| Varicose Veins | 8 |
Showing 5 of 34 disease areas.
Trials by start year as sponsor or collaborator (20)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 4 |
| 2024 | 5 |
| 2023 | 6 |
| 2022 | 5 |
| 2021 | 3 |
| 2019 | 2 |
| 2017 | 2 |
| 2015 | 1 |
| 2014 | 1 |
Showing 10 of 20 years.
Prediction, not a registry value: median of 23 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 5 months across 31 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 23% hit target (n=13) | 55% on time (n=11) |
Journals published in (14)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Plastic and reconstructive surgery. Global open | 2 |
| Techniques in coloproctology | 2 |
| Acta obstetricia et gynecologica Scandinavica | 1 |
| Burns : journal of the International Society for Burn Injuries | 1 |
| Diabetes care | 1 |
Showing 5 of 14 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 65 | 52 | 2025-12-30 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 1 |
FDA recalls (53)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| Aquacel Ag Surgical SP REF: 413556 9cm x 15cm/3.5 in. x 6 in., Sterile R | Class II | 2026-06-08 |
| Convatec, EsteemBody Drainable Pouch REF:423643, 10-45mm | Class II | 2026-02-16 |
| Convatec, EsteemBody Drainable Pouch REF:423653 10-35mm | Class II | 2026-02-16 |
| Convatec, EsteemBody Drainable Pouch REF:423657 10-35mm | Class II | 2026-02-16 |
| DuoDERM" Extra Thin dressings are highly flexible, control gel formula dressings designed for use on dry to lightly exudating wounds. DuoDERM" Extra Thin dressings are particularly suitable in areas subject to friction and those requiring contouring, e.g., elbows, heels. DuoDERM" Extra Thin dressings interact with wound moisture producing a soft mass that enables removal of the dressing with little or no damage to newly formed tissues. They help isolate the wound against bacterial and other external contamination. INDICATIONS " Management of superficial, dry to lightly exudating dermal ulcers. " Post-operative wounds. " Protective dressings. | Class II | 2025-08-29 |
Showing 5 of 53 recalls.
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 5 | 2023-03-02 |
Manufacturing and distribution sites (2)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| CONVATEC LIMITED | Deeside Flintshire, GB | FDA | |
| Convatec Limited | Deeside, GB | Health Canada |
Organization relationships (1)
| Related organization | Relationship | Evidence |
|---|---|---|
| ClinSearch | Co sponsors trial with | 1 |
Latest dated events (182)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-07 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-08 | FDA recall | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-02-16 | FDA recall | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-02-16 | FDA recall | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-02-16 | FDA recall | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
Showing 5 of 182 events.
Biomarker capability evidence (20)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABCC8 | Trial sponsor | Named in trial inclusion criteria |
| ABCC8 | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| H1-0 | Trial sponsor | Named in trial inclusion criteria |
| PVR | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 20 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, approved assets, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.